


TOWNSEND and TOWNSEND and CREW LLP

By: 
Yvonne Mock

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Daniel GREEN et al.

Application No.: 10/540,803

Filed: December 14, 2005

For: COMPOSITIONS AND METHODS
FOR THE PREVENTION AND
CONTROL OF INSULIN-INDUCED
HYPOGLYCEMIA

Confirmation No.: 7164

Examiner: Maury A. Audet

Art Unit: 1654

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08B form are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to

be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

A related application, App. No. 11/169,825, is pending. App. No. 11/169,825 claims priority to the instant application and is being examined by the same Examiner. It is understood that the Examiner is familiar with the status and prosecution of the '825 application, and has access to the file history via PAIR. However, should the Office require copies of any specifications or file histories the Office is urged to contact the undersigned.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Randolph Ted Apple
Reg. No. 36,429

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RTA:crf
61099450

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				<i>Application Number</i>	10/540,803
				<i>Filing Date</i>	June 23, 2005
				<i>First Named Inventor</i>	Green, Daniel T.
				<i>Art Unit</i>	1654
				<i>Examiner Name</i>	Maury A. Audet
Sheet	2	of	2	<i>Attorney Docket Number</i>	022354-000310US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	BANARER et al., "Intraislet Hyperinsulinemia Prevents the Glucagon Response to Hypoglycemia Despite an Intact Autonomic Response," <i>Diabetes</i> , 51:958-965	<input type="checkbox"/>
	AB	BOLLI et al., "Abnormal Glucose Counterregulation in Insulin-dependent Diabetes Mellitus, Interaction of Anti-Insulin Antibodies and Impaired Glucagon and Epinephrine Secretion," <i>Diabetes</i> , 32:134-141 (1983).	<input type="checkbox"/>
	AC	GERICH et al., "Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man," <i>Am. J. Physiol.</i> , 236(4):E380-E385 (1979).	<input type="checkbox"/>
	AD	PAOLISSO et al., "Pulsatile Rather Than Continuous Glucagon Infusion Leads to Greater Metabolic Derangements in Insulin-Dependent Diabetic Subjects," <i>Diabetes & Metabolism</i> , 16:42-47 (1990).	<input type="checkbox"/>
	AE	VELLA et al., "Effect of Glucagon-Like Peptide 1(7-36) Amide on Glucose Effectiveness and Insulin Action in People with Type 2 Diabetes," <i>Diabetes</i> , 49:611617 (2000).	<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.